Indaptus Therapeutics, Inc. (INDP) is trading at $0.8661, up 8.13 percent or $0.0651 during Tuesday's trading, after announcing the expansion of its Phase 1b/2 clinical trial of Decoy20.
The stock opened at $0.9450 and has traded between $0.8500 and $1.7000 so far, compared to a previous close of $0.8010 on the Nasdaq. Trading volume is 15.75 million shares, below the average volume of 23,844. The stock's 52-week range is $0.7010 to $3.1000.
The trial will now evaluate Decoy20 in combination with BeiGene's PD-1 checkpoint inhibitor, tislelizumab, focusing on safety, dose optimization, and early anti-tumor activity.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.